Sharif Moradi1,2, Thomas Braun3, Hossein Baharvand2,4. 1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 2. Department of Developmental Biology, University of Science and Culture, Tehran, Iran. 3. Max-Planck Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany. Electronic address: Thomas.braun@mpi-bn.mpg.de. 4. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Electronic address: Baharvand@Royaninstitute.org.
Embryonic stem cells (ESCs) are isolated from
blastocyst-stage embryos, and display multi-lineagedifferentiation potential and the ability to self-renew
indefinitely in culture (1-3). These two key characteristics
make ESCs invaluable tools for basic and appliedresearch on organismal development, drug discovery,
toxicological studies, and disease modeling (4, 5).
Serum-containing media supplemented with the leukemia
inhibitory factor (LIF) have been used to maintain ESCs
in an undifferentiated state (1, 2). In fact, serum provides
bone morphogenetic protein (BMP) signals which inhibit
neurogenesis while LIF blocks ESC differentiation into
mesendoderm as well as supports ESC clonogenicity (6).Importantly, culture media which contain inhibitors of
ESC differentiation have been found to maintain ESCs in
a more robust manner (7, 8). For example, R2i is a recently
developed ESC culture medium which exploits the ability
of small-molecule chemicals to inhibit endogenousdifferentiation signals in ESCs, i.e. transforming growth
factor-ß (TGF-ß) and extra-cellular regulated kinase
(ERK) pathways, thereby providing ESCs with a so-
called ground state of pluripotency which is much more
resistant to differentiation (9). ESC behavior is governed
by a network of transcription factors (TFs), signaling
pathways, chromatin regulators, and regulatory non-
coding RNAs (ncRNAs) (10-13). In this integrated gene
regulatory network (GRN), microRNAs (miRNAs) play
pivotal parts to sustain pluripotency and promote self-
renewal capacity (11, 14).miRNAs are ~22-nt long ncRNAs which regulate
a wide range of transcripts at the post-transcriptional
level, thereby controlling virtually all developmental
pathways and biological processes (15-18). These small
RNAs are dynamically expressed and play important
roles in different cellular states including during stem
cell differentiation and cell state transitions (15, 19).
ESCs express a specific set of miRNAs, and exhibit
major rearrangements in miRNA profiles upon exit from
pluripotency (20). Moreover, miRNAs are differentially
expressed and are functionally important over the
course of somatic cell reprogramming to pluripotency-a
process also known as induced pluripotent stem (iPS)
cell generation (15). ESC behavior is orchestrated by a
unique group of miRNAs, among which embryonic stem
cell cycle-regulating (ESCC) miRNAs represent the most
crucially important players (21, 22). ESCC miRNAs
include some members of miR-17 family, miR-290~295
cluster, and miR-302~367 cluster (23). ESCC miRNAs
have been shown to maintain ESC self-renewal in the
presence of differentiation-inducing miRNAs (let-7 family)
(24). However, it has remained uncharacterized whether
ESCC miRNAs can promote diverse aspects of stem cell self-
renewal in the absence of LIF, a situation which impairs the
undifferentiated maintenance of ESCs in terms of cell cycling,
clonogenicity, viability, and pluripotency gene expression. In
this study, we sought to determine whether miR-302b-3p, as
an ESCC miRNA belonging to miR-302~367 cluster, could
restore normal self-renewal to LIF-withdrawn ESCs. We
chose miR-302b-3p for functional analysis because i. It is
an ESCC miRNAs (the most functionally important class of
ESC miRNAs); and ii. It has been analyzed in the context of
iPS cell generation and wild-type ESCs to some extent, and
therefore we wanted to further investigate it in a new context
(i.e. LIF withdrawal) which has not been previously analyzed.
We observed that cell cycle defects of LIF-withdrawn ESCs
were rescued by miR-302b-3p. In addition, we found that
miR-302b-3p stimulated the viability of ESCs both in the
presence and absence of LIF and inhibited the increased cell
death induced by LIF removal. Overall, we report that miR302b-
3p is a potent driver of ESC self-renewal in the absence
of differentiation-inhibiting extrinsic signals.
Materials and Methods
Cell culture
In this experimental study, mouse ESCs (9) were cultured
on gelatin-coated tissue-culture plates (Sigma-Aldrich, USA)
in Knockout™ DMEM (Invitrogen, USA) supplemented
with 15% ES-qualified fetal bovine serum (HyClone,
UK), 2 mM L-glutamine (Invitrogen, USA), 0.1 mM nonessential
amino acids (Invitrogen, USA), 100 U/ml penicillin,
100 µg/ml streptomycin (Invitrogen, USA), 0.1 mM
ß-mercaptoethanol (Sigma-Aldrich, USA), and 1000 U/ml
mouseLIF (mLIF, Royan Biotech, Iran), and sub-cultured
every second day. R2i cells were cultivated in N2B27 media
consisting of Neurobasal® medium and DMEM/F-12 (both
from Invitrogen, USA) at a 1:1 ratio, 1% B27 supplement
(Invitrogen, USA), 1% N2 supplement (Invitrogen, USA),
0.1 mM non-essential amino acids, 5 mg/ml BSA(Invitrogen,
USA), 2 mM L-glutamine, 0.1 mM ß-mercaptoethanol, 100
U/ml penicillin, 100 µg/ml streptomycin, 1 µM PD0325901
(Stemgent, USA), 10 µM SB431542 (Sigma-Aldrich, USA),
and 1000 U/ml mLIF. This work was approved by the Ethical/
Scientific Committee of Royan Institute (Approval code:
Ec/93/1137).
Small RNA transfection
ESCs were transfected with 100 nM of miR-302b-3p
mimics (Dharmacon, miRIDIAN microRNA mimics,
Thermo Fisher Scientific, USA) according to the vendor’s
instructions. The scrambled small RNA control (Scr) or
the miR-302b-3p mimics as well as the DharmaFECT1
transfection reagent (Dharmacon, Thermo Fisher
Scientific, USA) were diluted in serum-free DMEM/F-12,
mixed, and incubated for 20 minutes at room temperature.
DharmaFECT1-small RNA complexes were added to
the culture media in a drop-wise manner. Assays were
performed with three biological replicates and the data
are represented as the mean ± SEM.
Alkaline phosphatase staining
To analyze alkaline phosphatase (AP) activity, cells
were rinsed with phosphate buffered saline (PBS), fixed
with a solution of acetone, 37% formaldehyde, and citrate
solution, washed with deionized water, and then stained
using a Leukocyte Alkaline Phosphatase Kit (Sigma-
Aldrich, USA) for 15 minutes at room temperature. Next,
the cells were washed with, and stored in, PBS.
Clonogenicity assay
ESCs (6.0×104 cells/well of 12-well plates) were transfected
with miR-302b-3p mimics 1 day after seeding. Three days
post-transfection, cells were replated at 5.0×103 cells/well
on gelatinized 24-well plates. On day 5 after replating, AP
staining was carried out, and undifferentiated (AP-positive)
and differentiated (AP-negative) ESC colonies were counted
to determine cloning efficiency.
Total RNAwas isolated using miRVana™ miRNAIsolation
Kit (Invitrogen, USA) or miRNeasy Micro Kit (Qiagen,
Germany) following the vendor’s instructions. To detect
mRNAs using quantitative reverse transcription-polymerase
chain reaction (qRT-PCR), 2 µl cDNA (12.5 ng) was used in
a 10 µl PCR reaction using the Power SYBR® Green PCR
Master Mix (Life Technologies, USA) and gene-specific
primers (Table 1). Expression of mRNAs was normalized
against Gapdh using the ΔΔCt method.
Table 1
Primer sequences used for quantitative reverse transcriptionpolymerase
chain reaction
Gene
Primer sequences (5ˊ-3ˊ)
Gapdh
F: GACTTCAACAGCAACTCCCAC
R: TCCACCACCCTGTTGCTGTA
Esrrb
F: AGGCTCTCATTTGGGCCTAGC
R: ATCCTTGCCTGCCACCTGTT
Rex1
F: TAGCCGCCTAGATTTCCACT
R: GTCCATTTCTCTAATGCCCAC
Dppa3
F: CTTTGTTGTCGGTGCTGAAA
R: GTCCCGTTCAAACTCATTTCC
Cdh1
F: GCTGGACCGAGAGAGTTAC
R: GGCACTTGACCCTGATACG
For detection and quantitation of miR-302b-3p using
qRT-PCR, cDNA was synthesized from 20 ng of total RNA
using miR-302b-3p-specific TaqMan miRNA RT primer
and amplified using a miR-302b-3p-specific TaqMan®
assay (Applied Biosystems, USA). snoRNA202 was used
as an internal normalization control. Reactions were run on
a StepOnePlus™ machine (Applied Biosystems, USA) in
triplicates and data were analyzed using the ΔΔCt method.Primer sequences used for quantitative reverse transcriptionpolymerase
chain reaction
Cell cycle analysis
ESCs were seeded at 2.0×105 cells/well in 6-well
plates 1 day prior to miR-302b-3p delivery, harvested
on day 3 post-transfection, rinsed with PBS, fixed with
ice-cold 70% ethanol, and then incubated at -20°C for
at least 2 hours before washing with ice-cold PBS. The
cells were resuspended in propidium iodide (PI)/RNase
Staining Buffer (12.5 µg/ml PI and 100 µg/ml RNase) and
incubated at room temperature for 15-30 minutes in the
dark. Flow cytometry was carried out using a BD LSR
II flow cytometer (BD Biosciences, USA) and the data
analysis was done with BD FACSDiva (BD Biosciences,
USA).
Cell viability assays
Live/dead viability assay
Cells were incubated with the reagent [0.1 µM ethidium
homodimer-1 and 0.1 µM calcein acetoxymethyl ester
(calcein AM) in PBS] from the Live/Dead® Viability/
Cytotoxicity Kit for Mammalian Cells (Molecular
Probes, USA) at room temperature for 30-60 minutes.
The cells were then washed with PBS and visualized
under fluorescence microscope (Olympus, IX71, Japan).
MTS viability assay
After removal of medium, the MTS reagent (Promega,
USA) was directly added to the wells in 96-well
plates, and the cells were then maintained in a 37°C
incubator for 1-3 hours. Cell viability measurements
were performed by determining absorbance at 495
nm on a Multiskan MCC microplate reader (Thermo
Fisher Scientific, USA).
miRNA target prediction and gene ontology analysis
TargetScan [www.targetscan.org (25)], miRanda
[http://www.microrna.org/ (26)],
and miRWalk [http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/ (27)]
tools were used to predict the potential mRNA targets
of miR-302b-3p. The predicted targets were subjected
to gene ontology (GO) Biological Process and
Wikipathways analyses using miRWalk and Enrichr
[http://amp.pharm.mssm.edu/Enrichr/ (28)]. Only
GO terms with a P<0.05 were considered statistically
significant and represented.
Statistical analysis
Data are shown as means ± SEM. Student’s t test was
used to analyze differences, and a P<0.05 was considered
statistically significant. GraphPad PRISMTM software was
used for data analysis.
First, we wanted to examine whether miR-302b-3p
could promote the viability of wild-type ESCs. To this
end, we confirmed that our miRNA delivery system was
efficient enough for miRNA overexpression. Mouse
embryonic fibroblasts (MEFs), which do not express this
miRNA, were seeded 1 day prior to miRNA treatment
and harvested for qRT-PCR analysis 1 day post-
treatment (Fig .1A). Our results showed that compared
to non-transfected control cells, MEFs transfected with
miR-302b-3p mimics highly expressed the mature
miRNA mimics (Fig .1B), indicating that our delivery
system was highly efficient. In addition, to assess the
efficiency of small RNA transfection into ESCs, we used
FITC-conjugated small RNAs for transient transfection
of ESCs. Our data using flow cytometry revealed that
24 hours post transfection, almost 60% of ESCs could
uptake the FITC-conjugated small RNAs (Fig .1C).
Fig.1
miR-302b-3p promotes ESC viability. A. Procedure of miR-302b-3p mimic delivery into MEFs, B. qRT-PCR analysis of miR-302b-3p expression levelfollowing miRNA transient transfection. Data areshown asmean ± SEM, n=3, C. The efficiency of FITC-small RNA transfection into ESCs asdetermined byflow cytometry 24 hours after transfection. Data areshown asmean ± SEM, n=3, D. Procedure of miR-302b-3p delivery into wild-type ESCs (serum+LIF)
for viability assessment, E. MTS assay of wild-type ESCs 3 days after treatment with miR-302b-3p. Data areshown asmean ± SEM, n=3 (*; P<0.05), F.
Procedure of miR-302b-3p transfection into LIF-withdrawn ESCs for viability assessment, and G. MTS assay of LIF-withdrawn ESCs 3 days after transfectionwith miR-302b-3p. Data areshown asmean ± SEM, n=3 (*; P<0.05).
Next, we treated wild-type ESCs with miR-302b3p
mimics and performed MTS assay 3 days posttransfection
(Fig .1D). Our data indicated that ESCs
treated with miR-302b-3p exhibited significantly
enhanced viability compared to the Scr control, as
manifested by MTS assay (Fig .1E). Therefore, miR302b-
3p mimics promote the viability of wild-type
ESCs. In addition, LIF-withdrawn ESCs were treated
with miR-302b-3p mimics (Fig .1F) and exhibited an
improved viability 3 days post-transfection (Fig .1G).
Overall, we conclude that miR-302b-3p increases the
viability of both serum+LIF and serum-LIF ESCs.
Embryonic stem cell clonogenicity is enhanced by
miR-302b-3p
We next asked if miR-302b-3p could regulate the
colony-forming efficiency of ESCs. To this end, ESCs
were seeded 1 day prior to miRNA transfection, reseeded
3 days post-transfection, and subjected to AP
staining 5 days after re-seeding (Fig .2A). We found
that the number of ESCs was significantly increased 3
days after treatment with miR-302b-3p compared to Scr
(Fig .2B). Moreover, we observed that on day 8, there
was a considerably larger number of AP-positive ESC
colonies after miR-302b-3p transfection, suggesting
that miR-302b-3p promoted the clonogenicity of
ESCs. Of note, the number of AP-negative colonies
was higher in miR-302b-3p-treated cells compared
to Scr-treated cells (Fig .2C), which might imply that
miR-302b-3p also stimulates exit from pluripotency.
However, we observed that the ratio of AP-positiveto
AP-negative colonies was higher in Scr than miR302b-
3p-treatment group (Fig .2D), suggesting that
miR-302b-3p limited the silencing of ESC self-renewal
program. Furthermore, we noticed that ESCs treated
with miR-302b-3p mimics exhibited a remarkably
higher AP activity, as evidenced by the enhanced AP
staining intensity in miR-302b-3p-trasfected cells
compared to the Scr control (Fig .2E). These data
indicate that miR-302b-3p is a potent driver of ESC
self-renewal.
Fig.2
Effect of miR-302b-3p on ESC cloning efficiency and AP activity. A. Procedure of clonogenicity analysis of ESCs after transfection with miR-302b3p,
B. Analysis of cell number 3 days after ESC treatment with miR-302b-3p. Data are
shown as
mean ± SEM, n=3 (*; P=0.0092), C. Cloning efficiency of
ESCs 8 days after ESC treatment with miR-302b-3p mimics. Data are
shown as
mean ± SEM, n=3 (*; P<0.05 and **; P=0.0015), D. Ratio of AP-positive ESC
colonies to AP-negative colonies 8 days after treatment with miR-302b-3p mimics, and E. Analysis of AP activity of ESCs treated with miR-302b-3p on day
8 post-transfection.
ESC; Embryonic stem cells and AP; Alkaline phosphatase.
miR-302b-3p promotes ESC viability. A. Procedure of miR-302b-3p mimic delivery into MEFs, B. qRT-PCR analysis of miR-302b-3p expression levelfollowing miRNA transient transfection. Data areshown asmean ± SEM, n=3, C. The efficiency of FITC-small RNA transfection into ESCs asdetermined byflow cytometry 24 hours after transfection. Data areshown asmean ± SEM, n=3, D. Procedure of miR-302b-3p delivery into wild-type ESCs (serum+LIF)
for viability assessment, E. MTS assay of wild-type ESCs 3 days after treatment with miR-302b-3p. Data areshown asmean ± SEM, n=3 (*; P<0.05), F.
Procedure of miR-302b-3p transfection into LIF-withdrawn ESCs for viability assessment, and G. MTS assay of LIF-withdrawn ESCs 3 days after transfectionwith miR-302b-3p. Data areshown asmean ± SEM, n=3 (*; P<0.05).ESC; Embryonic stem cells, MEFs; Mouse embryonic fibroblasts, qRT-PCR; Quantitative reverse transcription-polymerase chain reaction, and LIF; Leukemiainhibitory factor.Effect of miR-302b-3p on ESC cloning efficiency and AP activity. A. Procedure of clonogenicity analysis of ESCs after transfection with miR-302b3p,
B. Analysis of cell number 3 days after ESC treatment with miR-302b-3p. Data are
shown as
mean ± SEM, n=3 (*; P=0.0092), C. Cloning efficiency of
ESCs 8 days after ESC treatment with miR-302b-3p mimics. Data are
shown as
mean ± SEM, n=3 (*; P<0.05 and **; P=0.0015), D. Ratio of AP-positive ESC
colonies to AP-negative colonies 8 days after treatment with miR-302b-3p mimics, and E. Analysis of AP activity of ESCs treated with miR-302b-3p on day
8 post-transfection.ESC; Embryonic stem cells and AP; Alkaline phosphatase.
miR-302b-3p restores normal cell cycling to leukemia
inhibitory factor-withdrawn embryonic stem cells
ESCs have a unique cell division cycle which is tightly
regulated by numerous pluripotency-associated factors
including miRNAs (29-31). In fact, ESCC miRNAs
control key aspects of ESC cycling program which in
turn positively affects their pluripotency and unlimited
proliferation in culture. miR-302b-3p is a member of
ESCC miRNAs which play important roles in the cell
cycle fine-tuning of wild-type ESCs (21). However,
whether miR-302b-3p (and therefore ESCC miRNAs)
could promote ESC cycling in the face of LIF withdrawal
is not known. LIF removal is known to trigger ESCs to
exit from pluripotency by lengthening their G1 phase.We wanted to examine whether the introduction of
miR-302b-3p could restore normal cell cycling to LIF-
deprived ESCs which display a defective cell cycle
profile. To test this hypothesis, we removed LIF from
the ESC culture media and concomitantly added miR302b-
3p. Three days following treatment with miR-302b3p
mimics, cell cycle was assessed by flow cytometry
following PI staining (Fig .3A). Our data indicated that
LIF removal extended G1 phase in ESCs compared to
ESCs cultured under serum+LIF condition, which is in
agreement with previous findings (32, 33). Importantly,
we observed that miR-302b-3p significantly shortened
the extended G1 phase of LIF-deprived ESCs to levels
comparable to serum+LIF cells (Fig .3B, C). This result
indicated that miR-302b-3p restored normal cell cycling
to LIF-withdrawn ESCs. Moreover, we observed that LIF
removal triggered a significant increase in cell death rate.
However, miR-302b-3p treatment could compensate for
the absence of LIF by significantly reducing cell death
compared to the Scr control (Fig .3D). Taken together,
the defective cell cycle and enhanced cell death of LIF-
deprived ESCs are rescued by miR-302b-3p.
Fig.3
Cell cycle profiling of LIF-withdrawn ESCs treated with miR-302b-3p. A. Procedure of cell cycle analysis of LIF-deprived ESCs after transfection with
miR-302b-3p, B. Histograms of cell cycle profiles of wild-type ESCs aswell asLIF-withdrawn ESCs in the presence or absence of miR-302b-3p, C. Barplotshowing the cell cycle status of LIF-withdrawn ESCs in the presence or absence of miR-302b-3p using PI staining followed by flow cytometry 3 days post-
transfection. Data areshown asmean ± SEM, n=3 (*; P<0.05), and D. Percentage of wild-type ESCs and LIF-withdrawn ESCs in the presence or absenceof miR-302b-3p in sub-G1 phase 3 days post-transfection determined using PI staining followed by flow cytometry. Data arerepresented asmean ± SEM,
n=3 (*; P<0.05).
miR-302b-3p stimulates viability of ground-state
embryonic stem cells
Since miR-302b-3p promoted the viability of wild-type
ESCs as well as the normal cell cycling in the absence
of LIF, we then examined whether miR-302b-3p could
positively influence the viability of ESCs upon LIF
withdrawal. To provide a proper model for this analysis,
we cultured the cells in R2i+LIF, a culture condition
which consists of LIF plus small-molecule inhibitors of
FGF-ERK and TGF-ß signaling pathways and promotes
the ground state properties in ESCs (9). We then acutely
removed R2i chemicals as well as LIF from the culture
which led to a significant reduction in cell viability as well
as a marked increase in the rate of cell death (Fig .4A).
Our results indicated that 3 days after R2i/LIF removal,
the viability of R2i/LIF-withdrawn ESCs was markedly
diminished compared to ESCs grown in R2i+LIF
condition.
Fig.4
miR-302b-3p promotes the viability, and inhibits the death, of LIF-withdrawn ESCs. A. Procedure of ESC treatment with miR-302b-3p for viability
assessment and cell death analysis, B. Barplot showing the MTS assay of LIF-deprived ESCs 3 days after transfection with miR-302b-3p. Data are
represented
as
mean ± SEM, n=3 (*; P<0.05), C. Phase contrast image of R2i/LIF ESCs, R2i/LIF-withdrawn ESCs, and R2i/LIF-withdrawn ESCs treated with miR-302b-3p,
D. Live/dead immunofluorescence staining of R2i/LIF-withdrawn ESCs 3 days after miR-302b-3p transfection (scale bar: 100 µm), and E. Quantification of
the live (green), dead (red), and dying (yellow) cells shown in (D) using Image J.
LIF; Leukemia inhibitory factor and ESC; Embryonic stem cells.
Interestingly, we observed that miR-302b-3p could
significantly enhance the viability of R2i/LIF-deprived
ESCs compared to the Scr control and partially rescue
them (Fig .4B). R2i/LIF-withdrawn ESCs treated with
miR-302b-3p were also found to have larger colonies
(and therefore larger number of cells) compared to
the Scr control (Fig .4C), indicating that miR-302b-3p
inhibited the increased cell death rate induced by the
removal of LIF (and R2i).
To confirm the observation that miR-302b-3p stimulates
the viability of R2i/LIF-withdrawn ESCs, we analyzed
the degree of cell death following R2i/LIF withdrawal
using Live/Dead Staining Kit. Our results revealed that 3
days after addition of miR-302b-3p mimics (at the time of
R2i/LIF removal), there was a remarkably larger number
of green (live) cells compared to the Scr control which
displayed a much larger number of red (dead) and yellow
(dying) cells (Fig .4D, Fig 4E). These collective data indicated
that miR-302b-3p provision could partially compensate
for the lack of R2i chemicals and LIF in the maintenance
of ESC self-renewal.
miRNAs are known to regulate many cellular
processes in different contexts. Some miRNAs appear
to exert their cellular effects mainly through inhibiting
one or a few number of transcripts whereas others
fine-tune numerous transcripts to induce a certain
cellular phenotype (34). To examine if miR-302b-3p
treatment promote the expression of typical genes
associated with ESC pluripotency, we removed LIF
from ESC culture media and concomitantly treated
them with miR-302b-3p (Fig .5A). Our data showed
that 3 days after miRNA transfection, LIF-withdrawn
ESCs exhibited a stimulation of pluripotency gene
expression (Fig .5B), which suggests that miR-302b3p
contributes to the maintenance of LIF-withdrawn
ESCs by promoting ESC-specific gene expression.
Fig.5
qRT-PCR analysis of ESC-associated gene expression 3 days following miR-302b-3p transfection into LIF-withdrawn ESCs. Data are
shown
as
mean ± SEM, n=3 (*; P<0.05). A. Procedure of ESC treatment with miR-302b-3p mimics for pluripotency gene expression analysis and B.
Barplot indicating the expression pattern of pluripotency-associated genes 3 days post-transfection. Data are
represented as
mean ± SEM, n=3
(*; P<0.05).
Next, to gain insight into the putative biological
pathways regulated by miR-302b-3p in ESCs, we used
the TargetScan algorithm to obtain predicted targets
of miR-302b-3p. Based on family seed sequence
and target site conservation, TargetScan provided
predicted targets of miR-302 seed family
(Table S1)
(See supplementary Online Information at www.
celljournal.org) which we used for GO analysis. Our
GO Biological Process analysis of miR-302b-3p
predicted targets using Enrichr suggested that it might
control chromatin status as well as important pathways
associated with differentiation including organ
morphogenesis (Fig .6A). Moreover, Wikipathways
feature of Enricher suggested that typical signaling
pathways associated with ESC differentiation [FGFERK-(MAPK) and TGF-ß pathways (7, 9)] are
potentially targeted by miR-302b-3p. ESCs have a
distinct cell cycle and, interestingly, miR-302b-3p was
predicted to regulate cell cycle progression (Fig .6B).
Fig.6
Biological pathways potentially regulated by miR-302b-3p. A. Enrichr-based GO Biological Process analysis of miR-302b-3p targets predicted by
TargetScan and B. Enrichr-based Wikipathways analysis of miR-302b-3p targets predicted by TargetScan.
To evaluate the results obtained by Enrichr, we
simultaneously used three miRNA target prediction
tools (miRWalk, miRanda, and TargetScan). Our GO
Biological Process analysis using miRWalk (Table 2) suggested that different differentiation pathways,
chromatin structure, cell cycle, and TGF-ß signaling
are potentially regulated by miR-302b-3p, thereby
confirming the Enrichr results. Additionally, miR-302b
3p was predicted to inhibit epithelial to mesenchymal
transition (EMT) as well as apoptosis, which might
contribute to the maintenance of undifferentiated
ESCs. Taken together, miR-302b-3p appears to control
diverse cellular pathways to promote ESC self-renewal
in the absence and/or presence of LIF.
Table 2
miRWalk Biological Process analysis of miR-302b-3p predicted
targets
Pathway name
P value
Apoptotic process
5.98E-06
Chromatin modification
2.26E-05
Hemopoiesis
0.000146469
Cell cycle
0.001613578
Embryonic organ development
0.001729511
Axonogenesis
0.00241029
Neuron projection development
0.006984727
TGF-β signaling pathway
0.009703597
Muscle cell differentiation
0.008556945
B cell differentiation
0.011624291
Post embryonic development
0.012442256
Vasculature development
0.013997516
Forebrain morphogenesis
0.016093928
Spleen development
0.02050384
Endoderm development
0.030824682
Neuron differentiation
0.031794463
Cell fate commitment
0.03220361
Organ morphogenesis
0.038932781
Astrocyte differentiation
0.045223546
Epithelial to mesenchymal transition
0.044181992
Cell cycle profiling of LIF-withdrawn ESCs treated with miR-302b-3p. A. Procedure of cell cycle analysis of LIF-deprived ESCs after transfection with
miR-302b-3p, B. Histograms of cell cycle profiles of wild-type ESCs aswell asLIF-withdrawn ESCs in the presence or absence of miR-302b-3p, C. Barplotshowing the cell cycle status of LIF-withdrawn ESCs in the presence or absence of miR-302b-3p using PI staining followed by flow cytometry 3 days post-
transfection. Data areshown asmean ± SEM, n=3 (*; P<0.05), and D. Percentage of wild-type ESCs and LIF-withdrawn ESCs in the presence or absenceof miR-302b-3p in sub-G1 phase 3 days post-transfection determined using PI staining followed by flow cytometry. Data arerepresented asmean ± SEM,
n=3 (*; P<0.05).LIF; Leukemia inhibitory factor, ESC; Embryonic stem cells, and PI; Propidium iodide.miR-302b-3p promotes the viability, and inhibits the death, of LIF-withdrawn ESCs. A. Procedure of ESC treatment with miR-302b-3p for viability
assessment and cell death analysis, B. Barplot showing the MTS assay of LIF-deprived ESCs 3 days after transfection with miR-302b-3p. Data are
represented
as
mean ± SEM, n=3 (*; P<0.05), C. Phase contrast image of R2i/LIF ESCs, R2i/LIF-withdrawn ESCs, and R2i/LIF-withdrawn ESCs treated with miR-302b-3p,
D. Live/dead immunofluorescence staining of R2i/LIF-withdrawn ESCs 3 days after miR-302b-3p transfection (scale bar: 100 µm), and E. Quantification of
the live (green), dead (red), and dying (yellow) cells shown in (D) using Image J.
LIF; Leukemia inhibitory factor and ESC; Embryonic stem cells.qRT-PCR analysis of ESC-associated gene expression 3 days following miR-302b-3p transfection into LIF-withdrawn ESCs. Data are
shown
as
mean ± SEM, n=3 (*; P<0.05). A. Procedure of ESC treatment with miR-302b-3p mimics for pluripotency gene expression analysis and B.
Barplot indicating the expression pattern of pluripotency-associated genes 3 days post-transfection. Data are
represented as
mean ± SEM, n=3
(*; P<0.05).qRT-PCR; Quantitative reverse transcription-polymerase chain reaction, ESC; Embryonic stem cells, and LIF; Leukemia inhibitory factor.Biological pathways potentially regulated by miR-302b-3p. A. Enrichr-based GO Biological Process analysis of miR-302b-3p targets predicted by
TargetScan and B. Enrichr-based Wikipathways analysis of miR-302b-3p targets predicted by TargetScan.miRWalk Biological Process analysis of miR-302b-3p predicted
targets
Discussion
In the present study, we investigated the functional
significance of miR-302b-3p as an ESCC miRNA in
ESCs. We found that miR-302b-3p not only promoted
ESC viability in wild-type ESCs, but also enhanced
the cellular viability of LIF-withdrawn ESCs. It also
increased the number of undifferentiated ESC colonies
at the expense of differentiated ones, and stimulated
AP activity. miR-302b-3p inhibited the increased cell
death rate upon LIF withdrawal and provided LIF-
deprived ESCs with normal cell cycling typical of
wild-type ESCs.The observation that miR-302b-3p rescues LIF-
withdrawn ESCs might be due to the ability of
miR-302b-3p to inhibit multiple ESC-impairing
pathways that become activated upon LIF removal.
LIF is known to sustain ESC self-renewal through
activating JAK-STAT3 signaling pathway and to
inhibit differentiation in ESCs (6). Our bioinformatics
analysis suggested that miR-302b-3p might contribute
to the maintenance of LIF-withdrawn ESCs partly
by inhibition of differentiation. Consistent with our
GO analysis of miR-302b-3p predicted targets, miR302
seed family has been experimentally validated
to inhibit neuroectodermal differentiation (35, 36).
TGF-ßand MAPK pathways are also predicted to be
inhibited by miR-302b-3p. These two pathways are
well-known differentiation-affiliated pathways, and
their dual inhibition has been reported to promote
the establishment and maintenance of ground state
pluripotency in ESCs, a culture condition developed
recently which is called R2i (9). In principle, the
observation that R2i/LIF ESCs are partially rescued
by miR-302b-3p might be due to the miR-302b-3p
based inhibition of these two signaling pathways
that are normally inhibited in R2i culture. The point
that differentiation pathways might be inhibited by
miR-302b-3p in LIF-withdrawn ESCs can be best
explained by the fact that the miR-302~367 cluster
efficiently promotes the de-differentiation of somatic
cells into iPS cells in the presence and/or absence of
reprogramming TFs (15).It is known that LIF removal triggers exit from
the typical cell cycle of ESCs (i.e. prolongs G1
phase) (32, 33). We observed that miR-302b-3p
completely inhibited the G1 phase extension induced
by LIF removal. Indeed, miR-302b-3p (and other
ESCC miRNAs) has been observed to inhibit the G1
restriction point by suppressing retinoblastoma (Rb)
family of proteins, thereby protecting ESCs from
exiting the cell division cycle (37).LIF removal and therefore ESC differentiation
accompanies a process of EMT during which epithelial
ESCs turn into a mesenchymal cell state to start
differentiating (38, 39). miR-302 family of miRNAs
are predicted and also reported by Guo et al. (40) and
Liao et al. (41) to suppress EMT and apoptosis which
might also explain why miR-302b-3p markedly inhibits
cell death induced by R2i/LIF withdrawal. miR-302b3p
might also exert some of its diverse effects through
the regulation of chromatin status, as it gives rise to
chromatin opening and ESC-type gene expression
patterns during somatic cell reprogramming (15,
42). We conclude that ESCC miRNAs are integrated
into a robust GRN in ESCs to promote ESC survival
and undifferentiated self-renewal by modulating cell
cycle, differentiation, and cell death. It remains to be
experimentally determined how miR-302b-3p, and
probably other ESCC miRNAs, are able to stimulate
pluripotency maintenance in the absence of extrinsic
LIF signals.
Conclusion
ESCC miRNAs represent the most functionally
important class of miRNAs in ESCs. They are reportedly
able to oppose differentiation-affiliated miRNAs (let-7
family) in ESCs. Serum-grown ESCs depend on extrinsic
LIF signals to maintain self-renewal, and LIF-deprived
ESCs are not able to sustain their undifferentiated state.
In the present study, we examined if miR-302b-3p, as
an ESCC miRNA, was able to restore self-renewal to
LIF-withdrawn ESCs. Our data showed for the first
time that miR-302b-3p could promote cell cycling,
viability, pluripotency gene expression, AP activity,
and clonogenicity as well as decrease cell death in LIF-
withdrawn ESCs. We therefore conclude that ESCC
miRNAs promote diverse aspects of ESC self-renewal in
the absence of LIF.
Authors: Kathryn N Ivey; Alecia Muth; Joshua Arnold; Frank W King; Ru-Fang Yeh; Jason E Fish; Edward C Hsiao; Robert J Schwartz; Bruce R Conklin; Harold S Bernstein; Deepak Srivastava Journal: Cell Stem Cell Date: 2008-03-06 Impact factor: 24.633
Authors: R Coleman Lindsley; Jennifer G Gill; Theresa L Murphy; Ellen M Langer; Mi Cai; Mona Mashayekhi; Wei Wang; Noriko Niwa; Jeanne M Nerbonne; Michael Kyba; Kenneth M Murphy Journal: Cell Stem Cell Date: 2008-07-03 Impact factor: 24.633
Authors: Shi-Lung Lin; Donald C Chang; Chun-Hung Lin; Shao-Yao Ying; Davey Leu; David T S Wu Journal: Nucleic Acids Res Date: 2010-09-24 Impact factor: 16.971
Authors: Sophie A Hanina; William Mifsud; Thomas A Down; Katsuhiko Hayashi; Dónal O'Carroll; Kaiqin Lao; Eric A Miska; M Azim Surani Journal: PLoS Genet Date: 2010-10-21 Impact factor: 5.917
Authors: Sharif Moradi; Hamid Mahdizadeh; Tomo Šarić; Johnny Kim; Javad Harati; Hosein Shahsavarani; Boris Greber; Joseph B Moore Journal: Stem Cell Res Ther Date: 2019-11-21 Impact factor: 6.832